248 related articles for article (PubMed ID: 15017211)
61. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden.
Stattin P; Holmberg E; Bratt O; Adolfsson J; Johansson JE; Hugosson J;
J Urol; 2008 Dec; 180(6):2423-9; discussion 2429-30. PubMed ID: 18930283
[TBL] [Abstract][Full Text] [Related]
62. Prostate-specific antigen velocity in untreated, localized prostate cancer.
Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
[TBL] [Abstract][Full Text] [Related]
63. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
[TBL] [Abstract][Full Text] [Related]
64. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
65. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
[TBL] [Abstract][Full Text] [Related]
66. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
[TBL] [Abstract][Full Text] [Related]
67. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
[TBL] [Abstract][Full Text] [Related]
68. Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup.
Adolfsson J; Steineck G; Hedlund PO
J Urol; 1999 Feb; 161(2):505-8. PubMed ID: 9915436
[TBL] [Abstract][Full Text] [Related]
69. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
Zhu H; Roehl KA; Antenor JA; Catalona WJ
Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
[TBL] [Abstract][Full Text] [Related]
70. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
[TBL] [Abstract][Full Text] [Related]
71. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
72. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
73. Prostate cancer in Victoria in 1993: patterns of reported management.
Frydenberg M; Giles GG; Mameghan H; Thursfield VJ; Millar J; Wheelahan JB; Bolton DM; Syme RR
Med J Aust; 2000 Mar; 172(6):270-4. PubMed ID: 10860092
[TBL] [Abstract][Full Text] [Related]
74. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study.
Zietman AL; Chung CS; Coen JJ; Shipley WU
J Urol; 2004 Jan; 171(1):210-4. PubMed ID: 14665878
[TBL] [Abstract][Full Text] [Related]
75. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.
Tewari A; Johnson CC; Divine G; Crawford ED; Gamito EJ; Demers R; Menon M
J Urol; 2004 Apr; 171(4):1513-9. PubMed ID: 15017210
[TBL] [Abstract][Full Text] [Related]
76. Expectant management with selective delayed intervention for favorable-risk prostate cancer.
Klotz LH; Choo R; Morton G; Danjoux C
Can J Urol; 2002 Jun; 9 Suppl 1():2-7. PubMed ID: 12121587
[TBL] [Abstract][Full Text] [Related]
77. Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer.
Boutier R; Girouin N; Cheikh AB; Belot A; Rabilloud M; Gelet A; Chapelon JY; Rouvière O
BJU Int; 2011 Dec; 108(11):1776-81. PubMed ID: 21711432
[TBL] [Abstract][Full Text] [Related]
78. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer.
Choo R; Do V; Sugar L; Klotz L; Bahk E; Hong E; Danjoux C; Morton G; DeBoer G
Can J Urol; 2004 Feb; 11(1):2118-24. PubMed ID: 15003150
[TBL] [Abstract][Full Text] [Related]
79. Active surveillance for prostate cancer: an Australian experience.
Ischia JJ; Pang CY; Tay YK; Suen CF; Aw HC; Frydenberg M
BJU Int; 2012 Apr; 109 Suppl 3():40-3. PubMed ID: 22458492
[TBL] [Abstract][Full Text] [Related]
80. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series.
Adolfsson J; Steineck G; Hedlund PO
Urology; 1997 Nov; 50(5):722-6. PubMed ID: 9372882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]